Given that amyloid plaques were also observed in elderly persons who did not show pathological cognitive impairments and in many clinical trials targeting the reduction of brain Aβ deposition, and given that inhibition of tau aggregation was found to have little effect on AD cognitive decline and progression [33–36], new therapeutic strategies for AD are urgently needed. This evidence concerns the gene MAPT and Mental deterioration.